🩸 Additional insights on adverse events and management in Multiple Myeloma

#MultipleMyeloma #BCMA #GPRC5D #BispecificAntibodies #BsAbs #Immunotherapy #PlasmaCells #IVIG #Oncology #HemOnc #Hematology #ClinicalTrials #MajesTEC3 #HEMEHUB

🩸 More insights on bispecific antibody mechanisms and clinical development in Multiple Myeloma

#MultipleMyeloma #BispecificAntibodies #Immunotherapy #CancerImmunotherapy #GPRC5D #FcRH5 #TrispecificAntibodies #AntigenEscape #HemeOnc #HEMEHUB

IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients IASO Biotherapeutics announces significant results for RD118, its anti-GPRC5D CAR-T therapy, offering hope for multiple myeloma patients with few options left.

IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients #China #Shanghai #IASO_Bio #CAR-T #GPRC5D

GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial CT071 demonstrated an encouraging safety profile with compelling activity in patients with relapsed or refractory multiple myeloma.

Thérapie par #CAR_T 🧬 ciblée par #GPRC5D ( #CT071) pour le #MyélomeMultiple 🩸 R/R : 1er essai de phase 1 chez l’homme.
Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20).
www.thelancet.com/journals/lan...

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

✨ #CARsgen présente les résultats du #CT071 ( #CAR_T 🧬 autologue ciblant #GPRC5D) pour le traitement du #MyélomeMultiple 🩸 R/R dans le cadre d’un essai initié par l’investigateur ( #NCT05838131) ont été publiés dans "The Lancet Haematology 🩸"
www.prnewswire.com/news-release...

CARsgen Therapeutics Unveils Promising Results for CT071 in Treating Multiple Myeloma CARsgen Therapeutics has revealed encouraging results for its CT071 CAR T-cell therapy targeting GPRC5D in patients with relapsed/refractory multiple myeloma, documented in The Lancet.

CARsgen Therapeutics Unveils Promising Results for CT071 in Treating Multiple Myeloma #China #Shanghai #CAR-T #CARsgen #GPRC5D

Leads Biolabs Achieves Milestone with First Patient Dosed in LBL-034 Phase Ⅱ Trial Leads Biolabs announces the successful dosing of the first patient in the Phase Ⅱ trial of LBL-034, a bispecific T-cell engager aiming to target GPRC5D in cancer.

Leads Biolabs Achieves Milestone with First Patient Dosed in LBL-034 Phase Ⅱ Trial #Leads_Biolabs #GPRC5D #LBL-034

GPRC5D-directed therapies are reshaping the #MultipleMyeloma treatment landscape.🩸

Explore practical considerations with the use of GPRC5D-directed agents in our interactive expert feature. 🔍

Click here:
📖 buff.ly/PKlan0C

#MMsm #Myeloma #CellTherapy #ImmunoOnc #GPRC5D #HemOnc #BloodSky

#MultipleMyeloma #CAR_T #Talquetamab #RRMM #Oncology #Hematology #CellTherapy #RealWorldEvidence #MyelomaResearch #Immunotherapy #GPRC5D #BCMA

The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034 DelveInsight predicts significant growth in the GPRC5D-directed therapies market for relapsed multiple myeloma, driven by innovative treatments and rising demand.

The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034 #United_States #Las_Vegas #DelveInsight #GPRC5D #Myeloma

Featured today by @MSKLibrary: Phase I Trial of CARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
#CAR_TCellTherapy #MultipleMyeloma #GPRC5D #CancerResearch

ascopubs.org/doi/10.1200/...